We may be one step closer to saving thousands of newborns from a potentially nasty illness and death. A press release this month from Novavax, a clinical-stage biotechnology company, states that they have reached a milestone in their clinical trial for the highly anticipated vaccine for respiratory syncytial virus (RSV.)
What is RSV?
Although you may not have heard of it, the Centers for Disease Control and Prevention (CDC) states that almost all children have had RSV in the first two years of life. To put it into persepctive, the numbers of the morbidity and mortality of RSV are nearly identical to influenza virus. Indeed, more than 57,000 children under the age of 5 in the United States require hospitalization for RSV each year.
It is common...